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Abstract
Background: Chronic kidney disease (CKD) is known to expose the patient to a high risk of death due to
cardiovascular and infective causes. In parallel, septic shock is a major challenge for cardiovascular and immune
system. Therefore we tried to determine whether non-dialysis CKD, defined as a baseline estimated glomerular
filtration rate (eGFR) <60ml/min/1.73m2, for three months prior to the onset of septic shock is an independent risk
factor for death.
Methods: All patients treated in a teaching hospital medical ICU for septic shock between January 2007 and
December 2009 were retrospectively analyzed. Patients in whom baseline eGFR could not be determined (n=14)
or patients treated by chronic dialysis (n=21) or kidney transplantation (n=14) were excluded. A total of 163
patients were included. The population was divided according to baseline eGFR ≥ 60ml/min/1.73m2 (non-CKD
group, n=107) and < 60ml/min/1.73m2 (CKD group, n=56). Twenty-eight-day and 1-year survival curves were
plotted. Prognostic factors were determined using Cox proportional hazards models.
Results: Baseline eGFR was significantly higher in the non-CKD group than in the CKD group (81 (67–108) vs. 36
(28–44) ml/min/1.73m2, respectively; p=0.001). Age, SAPS II, serum creatinine on admission and the number of patients
with a history of diabetes, hypertension, heart failure, peripheral artery disease, coronary artery disease and statin
medication were significantly higher in the CKD group than in the non-CKD group. The mortality rate was lower in the
non-CKD group than in the CKD group after 28 days (50% vs. 70%, respectively; p=0.03) and 1 year (64% vs. 82%,
respectively; p=0.03). On multivariate analysis, the dichotomous variable CKD (eGFR < 60ml/min/1.73m2) remained
significantly associated with the 28-day and 1-year mortality.
Conclusions: Non-dialysis CKD appears to be an independent risk factor for death after septic shock.
Background
Septic shock is a major therapeutic problem in intensive
care units (ICUs) and constitutes a severe hemodynamic
and immune challenge for the patient. The high inci-
dence and high mortality rate associated to septic shock
resulted in an economic burden of nearly $17 billion per
year during the 90’s in the United States [1,2]. More re-
cently the average per-case cost for hospitalization due
to severe sepsis in ICU was estimated between 29,990
and 36,218$ [3].
Chronic kidney disease (CKD, defined by an estimated
glomerular filtration rate (eGFR) < 60ml/min/1.73m2
stable for more than three months) is estimated to affect
over 8 million people in the United States and these pa-
tients are exposed to increased risks of death, cardiovas-
cular events and hospitalization [4,5]. Moreover, CKD is
also an independent risk factor for death due to lung or
bloodstream infections [6,7]. Given that (i) CKD exposes
the patient to a high risk of death due to cardiovascular
and infective causes and (ii) septic shock is a major im-
mune and hemodynamic challenge, we decided to study
whether CKD prior to onset of septic shock is an inde-
pendent risk factor for death.* Correspondence: slama.michel@chu-amiens.fr
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We retrospectively analyzed all consecutive incident
patients treated for septic shock in the medical ICU of
our University medical center (Amiens, France) between
January 1st, 2007, and December 31st, 2009. Septic shock
was defined according to the international consensus state-
ment [8]. If patients experienced several episodes of septic
shock during hospitalization, only the first episode was ana-
lyzed. Patients were then classified according to their base-
line eGFR (defined as the eGFR during the 3 months
preceding septic shock). Baseline eGFR was calculated
using the four-variable Modification of Diet in Renal Di-
sease (MDRD) equation [5]. Patients were included in the
non-CKD group when they had a history of stable eGFR
(measured under stable conditions, e.g. during 2 scheduled
consultations) ≥ 60ml/min/1.73m2 during the 3 months
preceding the onset of septic shock. When this previous
eGFR was not available, the eGFR value after recovery from
septic shock was used and, when it was ≥ 60ml/min/
1.73m2 (in the absence of renal support), these patients
were included in the non-CKD group (n=32) assuming this
value to correspond to eGFR before the onset of septic
shock. Patients were included in the CKD group when they
presented a stable baseline eGFR < 60ml/min/1.73m2 for 3
months preceding the onset of septic shock.
Patients lacking longitudinal eGFR data and with an
eGFR < 60ml/min/1.73m2 after recovery from septic
shock were excluded from this study (n=14), as it was
impossible to determine whether or not the low post-
shock eGFR reflected their previous condition. Patients
on chronic hemodialysis or peritoneal dialysis (n=21)
and those who had undergone a kidney transplantation
(n=14) were also excluded from this study.
All patients were treated according to the international
guidelines for management of severe sepsis and septic
shock, except that (i) echocardiographic parameters (in-
stead of central venous pressure) were used to assess
fluid responsiveness and (ii) recombinant human acti-
vated protein C was not administered [8].
In accordance with French legislation, the local institu-
tional review board (CPPNord-Ouest II, Amiens Univer-
sity hospital, France) approved the study protocol.
Data collection
The following demographic data were collected for each
patient: age at admission, gender, history of diabetes,
hypertension, heart failure, peripheral artery disease,
coronary artery disease, COPD, statin administration,
admission for surgery or other reasons and infection
sites. Plasma hemoglobin and creatinine levels on ad-
mission were also recorded. The Simplified Acute Physi-
ology Score II (SAPS II) was recorded within 24 hours of
admission.
Onset of septic shock was considered to correspond to
administration of catecholamine. Non-ICU-acquired sep-
tic shock was defined as septic shock present on ICU ad-
mission or occurring within 48 hours of admission.
Acquired septic shock was defined as shock occurring
more than 48 hours after ICU admission. The number of
days without catecholamines or mechanical ventilation
was calculated by subtracting the number of days with cat-
echolamines or mechanical ventilation from 28 days or
the number of days until death or ICU discharge (if the
latter occurred within 28 days of admission) [9]. The
length of stay was defined as the number of days between
ICU admission and discharge or death. All patients were
classified according to the “Risk, Injury, Failure, Loss,
End-stage” (RIFLE) acute kidney injury criteria by taking
into account diuresis and plasma creatinine level during
the first 24 hours of septic shock [10].
Twenty-eight-day and one-year mortality rates after
onset of septic shock were calculated.
Statistical analysis
Data are expressed as median and interquartile range
(IQR). Proportions were compared by a Chi-square test
and quantitative variable were compared by a Mann–
Whitney test.
Patient survival curves were plotted according to the
Kaplan–Meier method and were compared in a Cox–
Mantel log rank test.
A Cox proportional hazards model was used to identify
baseline prognostic factors associated with 28-day and 1
year mortality. Univariate analysis initially tested all base-
line variables: age, gender, history of diabetes, hypertension,
heart failure, peripheral artery disease, coronary artery
disease, COPD, statin use, baseline eGFR, CKD status
(baseline eGFR < 60ml/min/1.73m2; yes or no), creatinine
on admission, hemoglobin (Hb) on admission and SAPS II.
The same variables were then tested in a backward multi-
variate Cox Regression analysis including baseline eGFR or
CKD status to predict 28-day or 1-year mortality.
A p value <0.05 was considered statistically significant.
All statistical analyses were performed using MedCalc




Between January 1st, 2007 and December 31st, 2009, a
total of 1,368 patients were admitted to the medical
ICU; 212 of these patients experienced septic shock as
defined by the international consensus statement [8].
Forty-nine patients were excluded from the study be-
cause they were on chronic hemodialysis (n=21), had
undergone kidney transplant (n=14) before their admis-
sion or lacked of baseline eGFR data (n=14).
Maizel et al. BMC Nephrology 2013, 14:77 Page 2 of 8
http://www.biomedcentral.com/1471-2369/14/77
One hundred sixty-three patients were analyzed, with
107 and 56 patients in the non-CKD and CKD groups, re-
spectively. The median delay between the calculation of
the baseline eGFR (considering the last stable serum cre-
atinine value available) and the onset of septic shock was
22 days (3–73). In 32 non-CKD patients, the eGFR was
determined after the recovery from the septic shock and
in the absence of renal support. The delay between the
end of the septic shock and the determination of the eGFR
in this population of 32 patients was 9.5 days (3–18).
Patient characteristics are presented in Table 1. Age,
serum creatinine on admission, serum creatinine at the
onset of septic shock and SAPS II were significantly
higher in CKD patients than in non-CKD patients. Simi-
larly, the number of patients with a history of diabetes,
heart failure, peripheral artery disease, coronary artery
disease, and statin medication was greater in the CKD
group than in the non-CKD group. The number of days
without catecholamines was significantly lower in the
CKD group. No significant inter-group differences were
observed in terms of gender, Hb on admission, need for
renal support, number of days without mechanical venti-
lation, length of stay and infection sites. Also the num-
ber of patients experiencing more than 1 septic shock
during their ICU stay was similar between the 2 groups
(2 (3.5%) CKD patients vs 9 (8.4%) non-CKD patients;
p=0.34). The most frequent infection sites were the
lungs (39%). As expected, baseline eGFR was signifi-
cantly lower in the CKD group than in the non-CKD
group (36 (28–44) vs. 81 (67–108) ml/min/1.73m2, re-
spectively; p=0.001).
The mortality rate was significantly higher in the CKD
group than in the non-CKD group after 28 days (70% vs.
50%, respectively; p=0.03) and after 1 year (82% vs. 64%,
respectively; p=0.03). Twenty-eight-day and one-year sur-
vival curves are shown in Figure 1. The CKD and non-
CKD curves differed significantly at both time-points but
mostly during the first 28 days of hospitalization.
Compared with survivors, patients who died within 28
days of onset of septic shock were older and presented a
higher SAPS II, a lower baseline eGFR, a lower number
of days without mechanical ventilation and catechol-
amines and a longer length of stay (Table 2). However,
no significant differences were observed for serum cre-
atinine on admission or at the onset of septic shock, Hb
on admission, gender, history of diabetes, hypertension,
heart failure, peripheral artery disease, coronary artery
disease, COPD or statin medication.
Effect of baseline eGFR on survival: univariate and
multivariate analyses
The results of univariate analysis for prediction of
28-day and 1 year mortality are presented in Table 3.
Age, baseline eGFR, CKD and SAPS II were significant
risk factors for 28-day mortality. The same variables and
the history of heart failure were also significant risk fac-
tors for 1-year mortality.
Multivariate Cox regression analysis demonstrated that
baseline eGFR or CKD status were independent predictive
factors of 28-day mortality after adjustments for multiple
confounders (age, gender, history of diabetes, hypertension,
heart failure, peripheral artery disease, coronary artery dis-
ease, COPD, statins, creatinine and Hb on admission)
(Table 4). CKD status (but not baseline eGFR) remained an
independent predictor of 28-day and 1-year mortality when
SAPS II was added to the previous list of confounders
(Tables 4 and 5).
Discussion
In this study, non-dialysis CKD and baseline eGFR were
found to be independent risk factors for death in septic
shock patients. The leading cause of death in CKD pa-
tients is cardiovascular disease, but it accounts for only
50% of overall mortality. The causes of the remaining
50% mortality have been less intensively studied. The
second leading cause of mortality in end-stage kidney
disease patients, after cardiovascular disease, is infec-
tious disease. Previous studies have clearly established
CKD as a strong risk factor for septicemia and lung in-
fection [11-13]. However, the prognosis of infections in
non-dialysis CKD patients has been less well studied,
despite the fact that the incidence of infectious disease
and the associated mortality rate in non-dialysis CKD
patients are known to be higher than in non-CKD popu-
lations [14]. Adult patients with bacteremia and serum
creatinine on admission >266 μmol/l are at increased
risk of death (although creatinine on admission does not
exactly reflect baseline GFR) [15]. In our study, serum
creatinine on admission was elevated but similar in both
survivors and non-survivors. This result suggests that
serum creatinine on admission is mainly the result of
septic-shock-related acute (but possibly reversible) kid-
ney damage and does not have the same prognostic im-
pact as chronic changes in baseline eGFR. James et al.
demonstrated that non-dialysis CKD patients are ex-
posed to a higher risk of lung infection and a higher risk
of death from lung infection [7]. They also observed an
increased risk of bloodstream infections and death from
community-acquired bloodstream infections in non-
dialysis CKD patients [6]. However, the study by James
et al. dealt with infections in general and did not specif-
ically focus on septic shock.
The mortality rate in our population of septic shock
patients (57% after 28 days) was similar to the usually
reported values of 40% to 70% [16,17]. Moreover, the
SAPSII-predicted hospital mortality of our population
was about 70%, which is fairly similar to the observed
rate of 65% [18]. In an observational cohort of more
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Table 1 Patient characteristics
Parameter Overall Non-CKD CKD p value between
Non-CKD and CKDn=163 n=107 n=56
Male gender 93 (57%) 58 (54%) 35 (62%) 0.4
Age (years) 66 (57–76) 63 (54–76) 72 (62–79) <0.001
Diabetes 51 (31%) 20 (19%) 31 (55%) 0.001
HBP 97 (59%) 58 (54%) 39 (70%) 0.08
Heart failure 26 (16%) 7 (6%) 19 (34%) 0.001
Peripheral artery disease 25 (15%) 9 (8%) 16 (28%) 0.002
Coronary artery disease 28 (17%) 11 (10%) 17 (30%) 0.003
COPD 27 (17%) 18 (17%) 9 (16%) 0.9
Statin use 41 (25%) 20 (19%) 21 (37%) 0.01
Admission
not related to surgery 145 (89%) 97 (91%) 48 (86%) 0.5
related to surgery 18 (11%) 10 (9%) 8 (14%) 0.4
ICU-acquired septic shock 11 (7%) 8 (7%) 3 (5%) 0.8
Baseline eGFR, (ml/min/1.73m2) 67 (44–92) 81 (67–108) 36 (28–44) <0.001
Scr on admission (μmol/l) 241 (137–415) 187 (116–305) 400 (300–520) <0.001
Scr onset of septic shock (μmol/l) 240 (131–390) 203 (102–332) 380 (236–469) <0.001
Hb on admission (g/dl) 10.2 (8.7-12.1) 10.2 (8.6-12.2) 10.2 (8.9-11.8) 0.6
SAPS II 60 (45–78) 58 (43–69) 66 (55–85) 0.005
Days w/o catechol (days) 2 (0–9) 3 (0–9) 0 (0–5) 0.02
Days w/o MV (days) 1 (0–5) 2 (0–5) 1 (0–5) 0.9
Length of stay (days) 7 (3–14) 8 (3–15) 5 (2–13) 0.1
Infection sites
lungs 64 (39%) 43 (40%) 21 (37%) 0.9
abdominal 25 (15%) 16 (15%) 9 (16%) 0.9
urinary 21 (13%) 12 (11%) 9 (16%) 0.5
cutaneous 12 (7%) 8 (7%) 4 (7%) 0.8
endocarditis 2 (1%) 0 2 (3%) -
bone 2 (1%) 1 (1%) 1 (2%) -
unknown 35 (21%) 25 (23%) 10 (20%) 0.5
RIFLE Classification 135 (83%) 86 (80%) 49 (87%) 0.4
Risk 25 (17%) 23 (21%) 2 (3%) <0.001
Injury 26 (19%) 16 (15%) 10 (18%) 0.3
Failure 78 (58%) 47 (44%) 31 (63%) 0.08
Loss of function 6 (4%) 0 6 (12%) -
ESKD 0 0 0 -
Renal support 75 (46%) 45 (42%) 30 (53%) 0.3
IHD 46 (33%) 29 (64%) 17 (57%) 0.9
CVVHDF 32 (23%) 19 (42%) 13 (43%) 0.6
CVVHF 16 (11%) 12 (27%) 4 (13%) 0.5
28-day mortality 93 (57%) 54 (50%) 39 (70%) 0.03
1-year mortality 115 (71%) 69 (64%) 46 (82%) 0.03
Reported as No. (%) or median (IQR).
CKD chronic kidney disease (Baseline eGFR <60ml/min/1.73m2), Scr serum creatinine, BMI body mass index, HBP High blood pressure, ICU intensive care unit, SAPS
II Simplified Acute Physiologic Score II, eGFR estimated glomerular filtration rate, adm. admission, MV mechanical ventilation, catechol. catecholamines, ESKD end-
stage kidney disease, IHD intermittent hemodialysis, CVVHDF continuous venovenous hemodiafiltration, CVVHF continuous venovenous hemofiltration.
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Figure 1 Kaplan-Meier survival curves after (A) 28 days (log rank test: X2=6.86, p=0.009) and (B) 1 year (log rank test: X2=7.67, p=0.006).
Table 2 Clinical and laboratory characteristics of survivors and non-survivors at 28 days
Survivors Non-survivors p
n=70 n=93
Male gender 44 (63%) 49 (53%) 0.2
Age (years) 64 (53–74) 71 (59–77) 0.01
Diabetes 23 (33%) 28 (30%) 0.9
HBP 39 (56%) 58 (62%) 0.4
Heart failure 9 (13%) 17 (18%) 0.4
Peripheral artery disease 12 (17%) 13 (14%) 0.8
Coronary artery disease 11 (16%) 17 (18%) 0.8
COPD 15 (21%) 12 (13%) 0.2
Statin use 18 (26%) 23 (25%) 0.9
Baseline eGFR (ml/min/1.73m2) 78 (61–106) 63 (38–82) 0.001
CKD 17 (24%) 39 (42%) 0.03
Scr on admission (μmol/l) 209 (122–409) 290 (175–426) 0.15
Scr at onset of septic shock (μmol/l) 232 (117–384) 270 (174–396) 0.2
Hb on admission (g/dl) 10.5 (8.2-12.7) 10 (8.8-11.7) 0.4
SAPS II 50 (40–62) 68 (56–90) <0.001
Days w/o catechol (days) 8 (3–14) 0 (0–2) <0.001
Days w/o MV (days) 5 (2–8) 0 (0–1) <0.001
Length of stay, days 12 (6–25) 4 (1–10) <0.001
RIFLE Classification 59 (44%) 76 (56%) 0.08
Risk 14 (56%) 11 (44%) 0.7
Injury 14 (54%) 12 (46%) 0.8
Failure 27 (35%) 51 (65%) 0.009
Loss of function 4 (67%) 2 (33%) 0.7
ESKD - - -
Reported as the number (%) or the median (IQR).
Scr serum creatinine, CKD chronic kidney disease (Baseline eGFR < 60ml/min/1.73m2), BMI body mass index, HBP High blood pressure, SAPS II Simplified Acute
Physiologic Score II, adm. admission, GFR glomerular filtration rate, MV mechanical ventilation, catechol. catecholamines.
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than 192,000 patients in the United States, Angus et al.
reported an increased mortality rate from severe sepsis
in CKD patients (36.7%), relative to the overall study
population (28.6%) [1]. However, this study concerned
sepsis rather than septic shock in particular and CKD
was not clearly defined. Similarly, Alberti et al. reported
an increased frequency of CKD in non-survivors from a
cohort of 3,608 infected ICU patients [19]. Annane et al.
looked for prognostic factors in a population of 8,250
septic shock patients in Europe and North America [16].
As in the study by Alberti et al., CKD was not reported
as an independent risk factor for death in septic shock.
However, Annane et al. did not clearly defined CKD and
did not specify whether chronically dialyzed patients and
kidney transplant patients were included in the analyses.
The strengths of our study are that it focuses on septic
shock (i.e. the most lethal infectious state) with CKD
defined according to international guidelines (i.e. as a
function of baseline GFR) [20].
In 14 patients we could not determine the eGFR in the
absence of stable serum creatinine before the septic
shock and the absence or abnormal eGFR after the epi-
sode. A proportion of those patients could be unknown
CKD patients or non-CKD patients suffering of chronic
Table 3 Univariate analysis of predictors of 28-day and
1-year mortality
28-day mortality 1-year mortality
HR (95% CI) p HR (95% CI) p
Male gender 1.25 (0.84-1.88) 0.27 1.02 (0.71-1.48) 0.89
Age 1.02 (1.01-1.04) 0.001 1.02 (1.01-1.04) 0.002
Diabetes 1.01 (0.65-1.58) 0.95 1.13 (0.76-1.66) 0.55
Hypertension 1.36 (0.89-2.07) 0.15 1.33 (0.91-1.93) 0.14
Heart failure 1.52 (0.90-2.57) 0.12 1.81 (1.19-2.75) 0.005
Peripheral artery disease 0.89 (0.50-1.60) 0.71 0.7 (0.54-1.51) 0.9
Coronary artery disease 1.20 (0.71-2.02) 0.5 1.08 (0.67-1.75) 0.74
COPD 0.69 (0.38-1.26) 0.23 0.93 (0.58-1.51) 0.78
Statin use 1.08 (0.68-1.73) 0.73 1.14 (0.75-1.73) 0.55
Baseline eGFR 0.99 (0.98-0.99) 0.006 0.99 (0.98-0.99) 0.004
CKD 1.69 (1.13-2.56) 0.01 1.67 (1.15-2.42) 0.007
Scr on admission 1.01 (0.99-1.01) 0.67 1.01 (0.99-1.01) 0.23
Scr at septic shock onset 1.02 (0.99-1.01) 0.71 1.01 (0.99-1.01) 0.26
Hb on admission 0.95 (0.88-1.03) 0.23 0.95 (0.88-1.01) 0.12
SAPS II 1.04 (1.03-1.05) 0.001 1.04 (1.03-1.05) 0.001
CI confidence interval, SAPS II Simplified Acute Physiologic Score II, GFR
glomerular filtration rate, CKD chronic kidney disease (Baseline eGFR <60ml/min/
1.73m2); Scr serum creatinine.
Table 4 Multivariate Cox regression analysis of baseline
risk factors for 28-day mortality
Hazard ratio 95% CI p
Model 1*
Age 1.02 1.01-1.03 0.04
Baseline eGFR 0.99 0.98-0.99 0.05
Model 2**
Age 1.02 1.00-1.04 0.01
CKD 1.54 1.01-2.35 0.04
Model 1 + SAPS II
SAPS II 1.04 1.03-1.05 0.001
Model 2 + SAPS II
Peripheral artery disease 0.48 0.25-0.93 0.03
CKD 1.7 1.08-2.68 0.02
SAPS II 1.04 1.03-1.05 0.001
*, Model 1 includes: Age, Gender, History of Diabetes, Hypertension, Heart
failure, Peripheral artery disease, Coronary artery disease, COPD, Statins,
Creatinine on admission, Hemoglobin on admission, Baseline eGFR.
**, Model 2 includes: Age, Gender, History of Diabetes, Hypertension, Heart
failure, Peripheral artery disease, Coronary artery disease, COPD, Statins,
Creatinine on admission, Hemoglobin on admission, CKD (Baseline
eGFR <60ml/min/1.73m2).
CI confidence interval, CKD chronic kidney disease, eGFR glomerular
filtration rate.
Table 5 Multivariate Cox regression analysis of baseline
risk factors for 1-year mortality
Hazard ratio 95% CI p
Model 1*
Age 1.02 1.01-1.03 0.01
Heart failure 1.83 1.18-2.83 0.007
Hemoglobin on admission 0.91 0.85-0.98 0.01
Model 2**
Age 1.02 1.00-1.04 0.004
Peripheral artery disease 0.56 0.32-0.98 0.04
Hemoglobin at admission 0.92 0.85-0.99 0.02
CKD 1.62 1.09-2.40 0.02
Model 1 + SAPS II
Heart failure 2.25 1.29-3.93 0.005
Coronary artery disease 0.40 0.21-0.77 0.006
Hemoglobin on admission 0.91 0.84-0.98 0.009
SAPS II 1.04 1.03-1.05 0.001
Model 2 + SAPS II
Heart failure 1.70 0.99-2.88 0.05
Peripheral artery disease 0.51 0.28-0.95 0.03
Coronary artery disease 0.49 0.26-0.93 0.03
Hemoglobin on admission 0.91 0.84-0.98 0.01
CKD 1.67 1.08-2.57 0.02
SAPS II 1.04 1.03-1.05 0.001
*, Model 1 includes: Age, Gender, History of Diabetes, Hypertension, Heart
failure, Peripheral artery disease, Coronary artery disease, COPD, Statins,
Creatinine on admission, Hemoglobin on admission, Baseline eGFR.
**, Model 2 include: Age, Gender, History of Diabetes, Hypertension, Heart
failure, Peripheral artery disease, Coronary artery disease, COPD, Statins,
Creatinine on admission, Hemoglobin on admission, CKD (Baseline
eGFR <60ml/min/1.73m2).
CI confidence interval, CKD chronic kidney disease, eGFR glomerular
filtration rate.
Maizel et al. BMC Nephrology 2013, 14:77 Page 6 of 8
http://www.biomedcentral.com/1471-2369/14/77
kidney failure after recovering from the septic shock.
Among those 14 patients, 9 (64%) died (all during the
first 28 days after the onset of septic shock). Even if we
hypothesized that those 14 patients all belonged to the
non-CKD group this would have only slightly modified
the 28 day mortality rate (from 50% to 52%) and the dif-
ference with the CKD mortality rate would remained
significant (p=0.033). It is also usually reported that RI-
FLE classification (defined as an increase of creatinine
above the baseline creatinine value) is associated with
mortality in septic shock patients [21]. In our study the
degree of AKI (RIFLE classification) was not predictive
of mortality. Although RIFLE is not a significant risk fac-
tor in the uni and multivariate analyses in our study, we
still find a significant difference between survivors and
non-survivors for the RIFLE Failure groups and close to
significant for the global RIFLE classification (p=0.08)
(Table 2). This partial result could be the consequence
of an insufficient number of patients. However this re-
sult could also result from a reduced increase of creatin-
ine during sepsis as suggested by a study in septic mice
by Doi et al. [22]. The authors showed a decreased pro-
duction of creatinine during sepsis in mice and in our
study this could have reduced the elevation of creatinine,
altering the RIFLE classification.
The introduction of SAPS II into the multivariate
models modified the relation between the different vari-
ables and the mortality. Generally speaking, the multi-
variate backward analyze introduces all the variables into
the model and than delete the variable that will im-
proves the most the predictive model by being deleted.
This process is repeated until no further improvement is
possible. In our study, the age dropped below the signifi-
cance threshold (Tables 4 and 5) when including SAPS
II in the different models meaning that the elimination
of the age improved the prediction of mortality. The rea-
son is that SAPS II is a predictive hospital mortality
score combining 17 different variables including the age.
This explains the stronger predictive value of SAPS II
than the age alone in our models.
Also the introduction of SAPS II raised the history of
peripheral artery disease (Model 2+SAPS II Table 4) and
coronary artery disease (Model 1 and 2+SAPS II Table 5)
above the significance threshold. This signifies that those
2 histories bring additional values to predict the mortality
that are not shared with SAPS II but were with the age.
The mechanisms linking CKD to increased mortality dur-
ing sepsis have not been fully elucidated, but hemodynamic
and immune causes may be involved. We can hypothesize
a possible role of the cardiovascular alterations linked to
CKD that could aggravate septic shock. The development
of left ventricular hypertrophy, diastolic dysfunction and/or
aortic stiffness related to even early stage of CKD is associ-
ated with higher cardiovascular morbidity and mortality [4].
In the context of septic hemodynamic stress, these abnor-
malities could be accentuated, resulting in increased mor-
tality. However, in the present study, CKD appeared to be a
risk factor independent of cardiovascular comorbidities.
Kidney failure and uremia are associated with severe alter-
ations in the immune system. The two mechanisms re-
quired for complete activation of T cells are compromised
[23,24]. After activation, T lymphocytes differentiate into
Th1 or Th2 lymphocytes that promote cell-mediated and
humoral immunity respectively. This differentiation is de-
pressed in uremic patients [25]. Moreover, in CKD, the
neutrophil count is not altered but neutrophils are less able
to kill microorganisms after phagocytosis [26].
Our findings in humans are supported by data from two
rodent models. Sepsis (induced by cecal ligature-puncture)
in mice with pre-existing CKD (created by 5/6th nephrec-
tomy or the injection of folic acid) was associated with a
higher mortality rate than in septic non-CKD mice
[27,28]. The presence of kidney dysfunction prior to sepsis
was associated with increased vascular permeability,
bacteremia, elevated vascular endothelial growth factor
and serum IL-10 levels and splenocyte apoptosis. More re-
cently, the increased release of high-mobility group box
protein 1 (HMGB1) and splenic apoptosis in septic CKD
mice has highlighted these pathways in the CKD/sepsis
interaction [28].
Our study is limited by its small sample size
preventing analysis of the effect of an eGFR between 30
and 59 ml/min/1.73m2 (stage 3 CKD) or between 15 and
29 ml/min/1.73m2 (stage 4 CKD) on risk factors in this
population, which could only be divided into two groups
(eGFR ≥ or < 60ml/Kg/1.73m2). It is also important to
note the high prevalence of CKD in our population of
patients hospitalized for septic shock in our medical
ICU (43% when taking into account the excluded
transplanted and chronically hemodialysis patients). As a
retrospective single-center study performed in a Neph-
rology Department’s medical ICU, patient recruitment
was probably biased towards CKD.
Conclusions
Non-dialysis CKD appears to be an independent risk fac-
tor for death after septic shock in ICU patients. These
results emphasize the importance of kidney function be-
fore onset of septic shock. Although the mechanisms
underlying this elevated mortality rate have yet to be ex-
plored, severe alterations of the cardiovascular and/or
immune systems may well play a major role.
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